Citadel Advisors
ABEO icon

Citadel Advisors’s Abeona Therapeutics ABEO Stock Holding History

Citadel Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$919K Buy
205,200
+147,700
+257% +$738K ﹤0.01% 7853
2025
Q4 		$303K Buy
+57,500
New +$289K ﹤0.01% 10129
2025
Q2 		– Sell
-5,600
Closed -$26.7K – 12305
2025
Q1 		$26.7K Sell
5,600
-2,400
-30% -$13.1K ﹤0.01% 12921
2024
Q4 		$44.6K Sell
8,000
-26,600
-77% -$164K ﹤0.01% 12506
2024
Q3 		$219K Sell
34,600
-4,900
-12% -$25.6K ﹤0.01% 9968
2024
Q2 		$167K Hold
39,500
– – ﹤0.01% 10183
2024
Q1 		$286K Buy
39,500
+28,900
+273% +$183K ﹤0.01% 9551
2023
Q4 		$53.1K Buy
+10,600
New +$46.6K ﹤0.01% 11725
2021
Q3 		– Sell
-744
Closed -$29K – 13707
2021
Q2 		$29K Sell
744
-696
-48% -$28.4K ﹤0.01% 13485
2021
Q1 		$68K Buy
1,440
+468
+48% +$25.8K ﹤0.01% 12747
2020
Q4 		$38K Sell
972
-324
-25% -$11K ﹤0.01% 10659
2020
Q3 		$33K Buy
1,296
+416
+47% +$26.2K ﹤0.01% 9731
2020
Q2 		$64K Buy
880
+392
+80% +$27.1K ﹤0.01% 9198
2020
Q1 		$26K Sell
488
-992
-67% -$66.3K ﹤0.01% 9226
2019
Q4 		$121K Sell
1,480
-164
-10% -$11.6K ﹤0.01% 8469
2019
Q3 		$93K Buy
1,644
+172
+12% +$12.9K ﹤0.01% 8516
2019
Q2 		$176K Sell
1,472
-1,792
-55% -$300K ﹤0.01% 8272
2019
Q1 		$601K Sell
3,264
-548
-14% -$98K ﹤0.01% 6474
2018
Q4 		$680K Buy
3,812
+2,464
+183% +$537K ﹤0.01% 5928
2018
Q3 		$431K Sell
1,348
-656
-33% -$233K ﹤0.01% 6931
2018
Q2 		$802K Sell
2,004
-920
-31% -$402K ﹤0.01% 5578
2018
Q1 		$1.05M Buy
2,924
+2,016
+222% +$749K ﹤0.01% 4734
2017
Q4 		$360K Sell
908
-128
-12% -$52.9K ﹤0.01% 6150
2017
Q3 		$442K Buy
+1,036
New +$278K ﹤0.01% 5497
2017
Q1 		– Sell
-432
Closed -$52K – 7363
2016
Q4 		$52K Buy
+432
New +$67.6K ﹤0.01% 6857

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ABEO Position: Q1 2026 in Review

Citadel Advisors reduced its Abeona Therapeutics (ABEO) stake by 56% in Q1 2026, selling an estimated $359K and leaving 55,837 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #10910.

Citadel Advisors first reported a position in ABEO in Q4 2016 and has held it in 26 quarters since. The position peaked at $24.5M in Q3 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Citadel Advisors held 55,837 shares of Abeona Therapeutics worth $250K as of Q1 2026.
  • Citadel Advisors sold 71,781 Abeona Therapeutics shares in Q1 2026, an estimated $359K.
  • Abeona Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10910 holding.
  • Citadel Advisors first reported a position in Abeona Therapeutics in Q4 2016 and has held it in 26 quarters since.
  • Citadel Advisors's Abeona Therapeutics position peaked at $24.5M in Q3 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.